Ajay S. Thatte

2 months ago | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

Correction to: Nature https://doi.org/10.1038/s41586-024-08291-2 Published online 11 December 2024In the version of the article initially published, in Fig. 2b, the x-axis label “µg β2-GPI per µg lipid” has now been amended to “µg ApoE per µg lipid”. In Fig. 2d, the x-axis label “µg ApoE per µg lipid” has now been amended to “µg β2-GPI per µg lipid”. In the key for Figs. 3e–j, “LNP + LNP 55” was incorrect and has now been amended to “LPS + LNP 55”.

Dec 11, 2024 | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

AbstractPre-eclampsia is a placental disorder that affects 3–5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide1,2. With no drug available to slow disease progression, engineering ionizable lipid nanoparticles (LNPs) for extrahepatic messenger RNA (mRNA) delivery to the placenta is an attractive therapeutic option for pre-eclampsia.

Dec 21, 2023 | nature.com | Lulu Xue |Ajay S. Thatte |Ningqiang Gong

AbstractImmunotherapy has emerged as an eminent and effective modality in the treatment of cancer. However, current cancer immunotherapies lack spatial and temporal control, resulting in systemic side effects and suboptimal patient outcomes. Responsive biomaterials have proven to be powerful tools for controlling cancer immunotherapies by providing precise control over the delivery and kinetics of immunotherapeutic cargoes.